News

Press Releases

• March 4, 2021

  Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio

  View

• January 6, 2021

  Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

  View

• September 16, 2020

  Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

  View

• September 16, 2020

  Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

  View

• August 4, 2020

  Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima

  View

• November 19, 2019

  Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)

  View

• June 18, 2019

  Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma

  View

• February 27, 2019

  Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

  View

• July 19, 2018

  Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer

  View

• March 1, 2017

  Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

  View